6 studies found for:    Open Studies | United States, Indiana | Community Regional Cancer Care
Show Display Options
Rank Status Study
1 Recruiting Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
2 Recruiting Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Conditions: Head and Neck Cancer;   Precancerous Condition
Interventions: Biological: cetuximab;   Drug: cisplatin
3 Recruiting Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Conditions: Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions: Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
4 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
5 Recruiting Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: accelerated radiation therapy;   Radiation: hypofractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: whole breast irradiation
6 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years